{"id":3323,"date":"2017-04-25T07:31:59","date_gmt":"2017-04-25T11:31:59","guid":{"rendered":"http:\/\/allphasepharma.com\/dir\/?p=3323"},"modified":"2025-09-20T19:09:15","modified_gmt":"2025-09-21T01:09:15","slug":"weak-correlation-antibiotic-action-mortality","status":"publish","type":"post","link":"https:\/\/allphasepharma.com\/dir\/2017\/04\/25\/3323\/weak-correlation-antibiotic-action-mortality\/","title":{"rendered":"The Weak Correlation Between Antibiotic Action and Mortality"},"content":{"rendered":"

\"\"<\/a><\/p>\n

At the recent FDA workshop on narrow-spectrum antibiotic development[1]<\/a>, the concept of using bacteriological response (BR) as an efficacy endpoint was flat-out rejected. The reason given is the purported lack of correlation between BR and survival\/mortality which FDA considers the most important clinical endpoint[2]<\/a>. FDA felt so strongly about this, that BR was not even considered a \u2018surrogate endpoint\u2019.<\/p>\n

We know for a fact and can all agree that bacteria cause disease, and that antibiotics kill bacteria or prevent their growth, first and foremost, and by so doing improve outcomes. Survival is the expected outcome for all but the most severe infections. Certainly, there are many bacterial infections that our immune system can take care of all by itself, but it is the immunosuppressed patient who has a hard time fending off even trivial bacterial infections without antibiotics. If antibiotics fail to protect such patients, the outcome is uniformly dismal.

Immunity, antibiotics, surgery, amputation, fire are the lines of defense, in that order\u2026<\/span><\/p>\n<\/div><\/p>\n

In the immune-compromised patient, bacterial persistence and mortality are tightly linked but in the normal host, only BR and CR are most directly correlated to antibiotic action. Our antibiotic trials are conducted in the immunologically intact host in whom with a high likelihood survival is expected. Study entry criteria make sure that high-risk patients are excluded; those who die during the 30-day observation period may succumb because of the infection but a myriad of other factors come into play: age, pre-existing conditions, trauma, surgery, complications, superinfections, you name it. Imagine an HAP\/VAP patient in the modern day ICU: intensive care can support vital organ functions with mechanical ventilation, dialysis, pressors and artificial coma, making \u201830-day survival\u2019 not a true measure of antibiotic efficacy; local medical practices and health care resources may have as much of an impact as the lowly antibiotic being tested.<\/p>\n

Not very long ago regulators insisted that the efficacy of a new AIDS antiviral be measured by its effect on mortality or on the prevention of opportunistic infections. It took years for FDA to accept VL as a surrogate endpoint. The recent flurry of HCV trials would not have been possible without acceptance of VL as a sensitive and specific response measure. Please note that for both HCV (and HBV) trials VL was an accepted surrogate efficacy measure long before it was validated on the basis of data showing that VL and progression to liver cirrhosis, the hard clinical endpoint, are indeed correlated. Nonetheless, the analogy to HIV led to early acceptance of VL as a reasonable outcome measure.<\/p>\n

For bacterial infections, we can test for culture-negativity at some infection sites but there are no straight-forward quantitative tests correlating bacterial disappearance rates and antibacterial effectiveness. We do know though for a fact that unchecked bacterial multiplication\u00a0will not get better on their own. Hence, we really do not need a \u2018bacterial load\u2019 test and follow its course because cure is always predicated on bacterial eradication.<\/p>\n

Even if we cannot distinguish antibiotic action from immunologic effect, why would we want to add more and unnecessary noise to the evaluation of antibiotic efficacy?<\/p>\n

Antibiotics are not fever medicines, or pain medicines or anti-inflammatory medicines. The only thing they do is \u2026kill bacteria. Secondary benefits are derived from this basic direct antibacterial effect. Yes, cough diminishes, fever comes down, WBC, interleukin and interferon levels normalize, and so do the PCT, ESR and CRP values. But the first necessary and sufficient step is bacterial eradication. Hence, let us not dismiss BR so fast; it is and should remain the primary read-out of antibiotic action. Mortality and other efficacy measures of lower sensitivity should take a back seat to BR.<\/p>\n

Abbreviations:
\n<\/strong>HAP\/VAP \u00a0 hospital-acquired \/ ventilator-associated pneumonia
\nBR \/ CR \u00a0 \u00a0 bacteriological \/ clinical response
\nVL \u00a0 \u00a0 viral load
\nPCT \u00a0procalcitonin test
\nESR \u00a0sed rate
\nCRP \u00a0C-reactive protein<\/p>\n

References:
\n<\/strong>[1]<\/a> FDA Briefing Document.\u00a0 Developing Antibacterial Therapies Targeting a Single Bacterial Species.\u00a0 Meeting of the Antimicrobial Drugs Advisory Committee (AMDAC). April 13, 2017
\n[2]<\/a> E Durante-Mangoni. Colistin and Rifampicin Compared With Colistin Alone for the Treatment of Serious Infections\u00a0Due to Extensively Drug-Resistant Acinetobacter baumannii: A Multicenter, Randomized Clinical Trial. CID 2013; 57: 349<\/p>\n","protected":false},"excerpt":{"rendered":"

At the recent FDA workshop on narrow-spectrum antibiotic development[1], the concept of using bacteriological response (BR) as an efficacy endpoint was flat-out rejected. The reason given is the purported lack of correlation between BR and survival\/mortality which FDA considers the most important clinical endpoint[2]. FDA felt so strongly about this, Continue reading The Weak Correlation Between Antibiotic Action and Mortality<\/span>→<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":3326,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[18],"tags":[2070,1271,403,2064,2067,2068,5,1583,2065,24,49,2066,833,2071,2072,2069,669,668],"class_list":["post-3323","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-the_viewpoint","tag-30-day-mortality","tag-allphase-pharma-consulting","tag-antibiotic-blog","tag-antibiotic-efficacy","tag-bacteriological-response","tag-clinical-response","tag-fda","tag-harald-reinhart","tag-hbv","tag-hcv","tag-hiv","tag-immunity","tag-mortality-endpoint","tag-outcome-variables-for-antibiotic-efficacy","tag-surrogate-endpoints","tag-survival","tag-viral-load","tag-vl"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/04\/Correlation-slider.jpg?fit=640%2C180&ssl=1","jetpack_shortlink":"https:\/\/wp.me\/p4KWFr-RB","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":4723,"url":"https:\/\/allphasepharma.com\/dir\/2025\/07\/13\/4723\/microbiological-response-as-primary-efficacy-endpoint-for-antibacterials\/","url_meta":{"origin":3323,"position":0},"title":"Microbiological Response as Primary Efficacy Endpoint for Antibacterials","author":"Harald","date":"July 13, 2025","format":false,"excerpt":"We have often mentioned the central importance of microbiological response as an endpoint in trials of antibacterials. This is contrary to other therapeutic areas, in which the etiology is less understood and where surrogate markers are needed. In bacterial infectious diseases we have the luxury of knowing exactly what causes\u2026","rel":"","context":"In "Did you know...?"","block_context":{"text":"Did you know...?","link":"https:\/\/allphasepharma.com\/dir\/category\/interesting_facts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/07\/HR_SLIDER-MICROBIOLOGY-STUPID.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/07\/HR_SLIDER-MICROBIOLOGY-STUPID.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/07\/HR_SLIDER-MICROBIOLOGY-STUPID.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":1301,"url":"https:\/\/allphasepharma.com\/dir\/2015\/03\/15\/1301\/the-new-cuti-guideline-a-look-at-the-evolving-thinking-at-fda\/","url_meta":{"origin":3323,"position":1},"title":"The New cUTI Guideline: A Look at the \u2018Evolving Thinking\u2019 at FDA","author":"Harald","date":"March 15, 2015","format":false,"excerpt":"Just to refresh everyone\u2019s memory: First, we had the Points-To-Consider document of 1993, then the 1998 Guidance, followed by the 2012 Guidance and now the 2015 Guidance for the conduct of registration studies in cUTI.\u00a0 They all have served us well and I cannot recall a situation when a drug\u2026","rel":"","context":"In "The News"","block_context":{"text":"The News","link":"https:\/\/allphasepharma.com\/dir\/category\/the_news\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":4964,"url":"https:\/\/allphasepharma.com\/dir\/2025\/08\/15\/4964\/new-idsa-cuti-guideline\/","url_meta":{"origin":3323,"position":2},"title":"NEW IDSA cUTI GUIDELINE","author":"Harald","date":"August 15, 2025","format":false,"excerpt":"A new Guideline for the treatment of cUTI just arrived.[1] First, we are glad that this somewhat mundane topic receives the attention it deserves.\u00a0 UTIs are often downplayed as minor infections, but the cUTI variety should not be taken lightly.\u00a0 Many patients still are admitted with life-threatening infections, so prompt\u2026","rel":"","context":"In "The News"","block_context":{"text":"The News","link":"https:\/\/allphasepharma.com\/dir\/category\/the_news\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/08\/cUTI-classification.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/08\/cUTI-classification.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/08\/cUTI-classification.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/08\/cUTI-classification.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/08\/cUTI-classification.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]},{"id":4089,"url":"https:\/\/allphasepharma.com\/dir\/2025\/03\/28\/4089\/gepotidacin-absssi-fail-adaptively\/","url_meta":{"origin":3323,"position":3},"title":"Gepotidacin ABSSSI – How to Fail Adaptively,","author":"Harald","date":"March 28, 2025","format":false,"excerpt":"Study Design in ABSSSI \u2013 A Statistician\u2019s Delight The design of the O\u2019Riordan ABSSI study [1] deserves comment.\u00a0 This was a double-blind study of 2 lower dose arms (Part 1) with an add-on open-label (Part 2) high-dose arm. The pimary endpoint was a non-standard composite efficacy and safety endpoint that\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/03\/HR_Gepotidacin-slider.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/03\/HR_Gepotidacin-slider.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/03\/HR_Gepotidacin-slider.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":1265,"url":"https:\/\/allphasepharma.com\/dir\/2015\/02\/11\/1265\/commenting-on-comments-the-ceftaroline-trial-program-in-cabp\/","url_meta":{"origin":3323,"position":4},"title":"Commenting on Comments:\u00a0 The Ceftaroline Trial Program in CABP","author":"Harald","date":"February 11, 2015","format":false,"excerpt":"The ceftaroline (Teflaro\u00ae) program was executed at a time when FDA was debating a new CABP Guidance with new outcome measures: no longer was the time-honored TOC assessment acceptable, instead improvement on Day 3-5 was to become the new primary endpoint.\u00a0 FDA made other significant changes to the old 1998\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"Teflaro Ad CAP","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/02\/Teflaro-Ad-CAP.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/02\/Teflaro-Ad-CAP.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/02\/Teflaro-Ad-CAP.jpg?resize=525%2C300 1.5x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/02\/Teflaro-Ad-CAP.jpg?resize=700%2C400 2x"},"classes":[]},{"id":2064,"url":"https:\/\/allphasepharma.com\/dir\/2015\/10\/22\/2064\/polyphor-pol7080-and-the-journey-to-the-land-of-pyocyanea-part-3\/","url_meta":{"origin":3323,"position":5},"title":"Polyphor POL7080 And The Journey to The Land of Pyocyanea (Part 3)","author":"Harald","date":"October 22, 2015","format":false,"excerpt":"VABP is clearly the main\u00a0indication to be pursued by a drug like POL7080.\u00a0 Here is the question: How to conduct a study demonstrating efficacy for a drug which only has a\u00a0single-organism spectrum? \u00a0Which is actually no spectrum at all. \u00a0Existing guidelines for the development of ID drugs are indication-driven, with\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"bridge Pyocyanea-P3","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/10\/bridge-Pyocyanea-P3.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/10\/bridge-Pyocyanea-P3.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/10\/bridge-Pyocyanea-P3.jpg?resize=525%2C300 1.5x"},"classes":[]}],"jetpack_likes_enabled":true,"_links":{"self":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/3323","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/comments?post=3323"}],"version-history":[{"count":3,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/3323\/revisions"}],"predecessor-version":[{"id":3327,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/3323\/revisions\/3327"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media\/3326"}],"wp:attachment":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media?parent=3323"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/categories?post=3323"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/tags?post=3323"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}